Noninvasive Continuous Measurement of SpHb After Spontaneous Vaginal Delivery

January 5, 2012 updated by: Silvia Stirparo, Città di Roma Hospital

Determination of the Physiological Reference Values of Trend of Hemoglobin in the Post-partum Period After Spontaneous Vaginal Delivery. A Sequential Pilot Study Using the Noninvasive Continuous Technology of SpHb

Aim of this study is to determine the physiological reference individual values (RI) of maternal continuous SpHb immediately after delivery in the post-partum period (continuous monitoring up to 2 hours after delivery) in order to establish the physiological Hb variations in response to the physiological blood loss due to delivery.

During labor all parturients will be tested for standard Laboratory Hb and monitored for at least 30 minutes with SpHb monitoring equipment (Radical-7™ Pulse CO-Oximeter and Rainbow DiSposable™ Adult Adhesive Sensor), and these values will be considered to be the baseline values.

Immediately after spontaneous vaginal delivery, venous blood sample will be taken for Hb determination and Radical 7 equipment for SpHb will be connected to the patient's finger and will be recorded for at least two hours after delivery. At the end of this period of observation a venous blood sample will be taken for Hb determination. Additional measurements of both SpHb and Lab Hb will be performed 24 hours after delivery.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Background and Significance:

Pregnancy and childbirth involve health risks, even for women without any pre-existing health problems. Postpartum hemorrhage is one of most common complications for delivering mothers and causes 19% of in-hospital maternal deaths (Bateman BT et al. "The Epidemiology of Postpartum Hemorrhage in a Large, Nationwide Sample of Deliveries" Anesthesia and Analgesia 2010 110:1368-1373) . Due to pregnancy physiological changes, maternal bleeding is typically discovered after a significant change in vital signs, and/or symptoms, and usually confirmed with an invasive laboratory hemoglobin test. This can result in late detection of bleeding that can affect patient outcome. Early detection of signs and symptoms of obstetric hemorrhage is therefore crucial. Non-invasive and continuous hemoglobin (SpHb) monitoring system quickly measures current hemoglobin levels and continuously tracks them in real-time to detect falling hemoglobin levels that may, in turn, represent an early sign of a potential hemorrhage. Unfortunately there is no validation of the clinical accuracy of the Rainbow device for the noninvasive and continuous hemoglobin (SpHb) monitoring in the obstetric setting nor any information concerning its use as a tool for the early detection of postpartum hemorrhage.

The investigators therefore propose to undertake an open, preliminary, sequential pilot study to determine the physiological values (RI) of maternal continuous SpHb in the post-partum period.

Study Objective:

To determine the physiological reference individual values (RI) of maternal continuous SpHb immediately after delivery in the post-partum period (continuous monitoring up to 2 hours after delivery) in order to establish the physiological Hb variations in response to the physiological blood loss due to delivery.

Inclusion and exclusion criteria

Healthy parturients in labor will be asked to be enrolled in the study and informed consent will be obtained.Parturients will be consecutively included in this study. Bleeding risk subjects will be excluded (parturients who had:

Operative or instrumental vaginal delivery,Estimated blood loss greater than 500 mL, who had II and III degree perineal lacerations, any coagulation disorder or anticoagulant therapy)

Sample Size Since we have no available information on the expected distribution of the outcome, we will use a sequential design. The main endpoint of our analysis will be a reliable estimate for the outcome expected in healthy women after labor.

The investigators will state their target estimate as being reliable when the ratio between the estimate and its standard error is smaller than 2.

The International Federation of Clinical Chemistry (IFCC) and Clinical Laboratory and Standards Institute (CLSI) guidelines in 2008 recommended to establish RIs with at least 120 reference individuals using the nonparametric ranking method (Clinical and Laboratory Standards Institute. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd ed. Wayne, PA: CLSI; 2008) and thus we will include in the study a sample of at least 120.

Methods During labor all parturients will be tested for standard Laboratory Hb and monitored for at least 30 minutes with SpHb monitoring equipment (Radical-7™ Pulse CO-Oximeter and Rainbow DiSposable™ Adult Adhesive Sensor), and these values will be considered to be the baseline values.

Immediately after spontaneous vaginal delivery, venous blood sample will be taken for Hb determination and Radical 7 equipment for SpHb will be connected to the patient's finger and will be recorded for at least two hours after delivery. At the end of this period of observation a venous blood sample will be taken for Hb determination. Additional measurements of both SpHb and Lab Hb will be performed 24 hours after delivery.

According to the SpHB data collection-research protocol, sensor site will be connected to the patient's ring finger of the non-dominant hand. Sensor handling and placement will also follow the instructions of the SpHB data collection-research protocol.

Sensor will be attached to the same arm as the blood draw. Sensor placement on the hand of the side with the blood pressure cuff will be avoided unless they are drawing blood from that extremity. Placing the sensor and drawing blood from the same arm that is being used for IV infusions will be also avoided.

SpHb results will be not included when the Perfusion Index (PI, noninvasive index of peripheral perfusion and vasomotor tone) values will be less than 0.5.

Concerning blood sampling, blood will be drawn directly into the vacutainer by using a needle no smaller than 20G and analyzed within 15 min of the blood draw.

In Vivo adjustment and Trend Accuracy

SpHb accuracy with an in vivo adjustment will be calculated by using the new Radical 7 equipment with in vivo adjustment feature software which will take the bias between the first SpHb and first laboratory tHb measurement and will adjust all subsequent measurements for that case.

The trend accuracy will be calculated by using the following time points: pre-delivery, 2 hrs after delivery and 24 hr after delivery.

Calibrated SpHb measurements will be compared to subsequent laboratory values to create a Bland Altman plot and calculate bias, and confidence interval.

Study Type

Interventional

Enrollment (Anticipated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Italy
      • Roma, Italy
        • Recruiting
        • Citta di Roma Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Silvia Stirparo, MD
        • Principal Investigator:
          • Giorgio Capogna, MD
        • Principal Investigator:
          • Gabriele Tola, MD
        • Principal Investigator:
          • Luca Ruggeri, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Healthy parturients in labor

Exclusion Criteria:

  • Parturient with coagulation defects, or with anticoagulant therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: SINGLE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SpHb monitoring equipment (Radical-7™ Pulse CO-Oximeter and Rainbow DiSposable™ Adult Adhesive Sensor, Masimo, Irvine, CA. Continuous Hemoglobin evaluation, measure unit: g/dL
Time Frame: 24 hours postpartum
To determine the physiological reference individual values (RI) of maternal continuous SpHb immediately after delivery in the post-partum period (continuous monitoring up to 2 hours after delivery) in order to establish the physiological Hb variations in response to the physiological blood loss due to delivery.
24 hours postpartum

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Città di Roma Hospital

Investigators

  • Principal Investigator: Silvia Stirparo, MD, Citta di Roma Hospital
  • Study Chair: Giorgio Capogna, MD, Cittàdi Roma Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2011

Primary Completion (ANTICIPATED)

March 1, 2012

Study Completion (ANTICIPATED)

May 1, 2012

Study Registration Dates

First Submitted

December 28, 2011

First Submitted That Met QC Criteria

January 5, 2012

First Posted (ESTIMATE)

January 6, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

January 6, 2012

Last Update Submitted That Met QC Criteria

January 5, 2012

Last Verified

January 1, 2012

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • Postpartum non invasive Hb

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delivery Uterine

Clinical Trials on continuous Hb monitor

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe